Status:
COMPLETED
BETERNet Notch Signaling and Novel Biomarkers for Barretts Esophagus
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Conditions:
Barrett's Esophagus
Eligibility:
All Genders
18+ years
Brief Summary
This research study hopes to identify new molecular markers in the tissue of Barrett's esophagus that will help physicians better understand and manage this condition. Patients undergoing an upper end...
Detailed Description
This research study hopes to identify new molecular markers in the tissue of Barrett's esophagus that will help physicians better understand and manage this condition. Currently there is very little u...
Eligibility Criteria
Inclusion
- For BE patients:
- History of histologically confirmed BE, defined as endoscopically-suspected BE with intestinal metaplasia with globlet cells on esophageal biopsies,
- BE length C1M1 or C0M2
- Age 18 years
Exclusion
- History of gastric or esophageal surgery
- Inability to give informed consent
- Erosive esophagitis seen on upper endoscopy
- History of prior endoscopic therapy for BE 5 (for controls) History of intestinal metaplasia on previous esophageal, GE junction or cardia biopsies.
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2018
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01484925
Start Date
November 1 2011
End Date
November 1 2018
Last Update
December 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19104